|
Tumor response and associated median survival (n = 39) |
|||
| No. of patients |
Median survival (range) |
95% CI |
|
|
|
|||
| Complete response (CR) |
2 (5%) |
> 51 months* |
|
| with concomitant treatment (RFTA) |
1 |
(> 51 months*) |
|
| without concomitant treatment |
1 |
(> 51 months*) |
|
|
|
|||
| Partial response (PR) |
5 (13%) |
18 months |
14–22 |
| with concomitant treatment (TACE/RFTA) |
2 |
(range 15.7–55.4) |
|
| without concomitant treatment |
3 |
(range 3.9–24.8) |
|
|
|
|||
| Stable disease (SD) |
24 (61%) |
14 months |
11–17 |
| Progressive disease (PD) |
8 (21%) |
4 months |
0 – 8 |
| Objective response (CR+PR) |
7 (18%) |
25 months |
20–29 |
| Tumor control rate (CR+PR+SD) |
31 (79%) |
16 months |
11–20 |
|
* patients alive at time of analysis | |||
Dollinger et al. BMC Cancer 2008 8:72 doi:10.1186/1471-2407-8-72 |
|||